A phase II study of intravenous DX-8951f (exatecan mesylate) administered daily for five days every three weeks to pediatric and young adult patients with Ewing's sarcoma (ES), primitive neuroectodermal tumor (PNET), or desmoplastic small round cell tumor (DSRCT)
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Exatecan (Primary)
- Indications Ewing's sarcoma; Sarcoma
- Focus Therapeutic Use
- 15 May 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.